Mylan NV (NASDAQ:MYL) Shares Bought by Chevy Chase Trust Holdings Inc.

Share on StockTwits

Chevy Chase Trust Holdings Inc. raised its holdings in Mylan NV (NASDAQ:MYL) by 0.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 432,379 shares of the company’s stock after buying an additional 1,129 shares during the period. Chevy Chase Trust Holdings Inc.’s holdings in Mylan were worth $8,552,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of MYL. Vanguard Group Inc. grew its holdings in shares of Mylan by 19.2% during the second quarter. Vanguard Group Inc. now owns 56,048,375 shares of the company’s stock worth $1,067,160,000 after purchasing an additional 9,026,215 shares during the last quarter. Banco Santander S.A. purchased a new position in shares of Mylan during the third quarter worth about $55,384,000. Nuveen Asset Management LLC grew its holdings in shares of Mylan by 824.3% during the second quarter. Nuveen Asset Management LLC now owns 1,681,501 shares of the company’s stock worth $31,898,000 after purchasing an additional 1,499,579 shares during the last quarter. Point72 Asset Management L.P. grew its holdings in shares of Mylan by 312.6% during the second quarter. Point72 Asset Management L.P. now owns 1,769,543 shares of the company’s stock worth $33,692,000 after purchasing an additional 1,340,643 shares during the last quarter. Finally, AQR Capital Management LLC grew its holdings in shares of Mylan by 11.0% during the second quarter. AQR Capital Management LLC now owns 11,247,227 shares of the company’s stock worth $213,473,000 after purchasing an additional 1,111,009 shares during the last quarter. Institutional investors own 86.54% of the company’s stock.

In other Mylan news, insider Goulds Bruce 8,000,000 shares of Mylan stock in a transaction on Friday, November 8th. 0.81% of the stock is currently owned by insiders.

MYL has been the topic of several research reports. Morgan Stanley lowered Mylan from an “overweight” rating to an “equal” rating and dropped their price objective for the stock from $25.00 to $18.00 in a report on Thursday, November 7th. SunTrust Banks raised their price objective on Mylan from $25.00 to $27.00 and gave the stock a “buy” rating in a report on Thursday, September 12th. Cfra raised Mylan to a “hold” rating in a report on Wednesday, November 27th. Evercore ISI reaffirmed a “buy” rating on shares of Mylan in a report on Friday, August 9th. Finally, ValuEngine raised Mylan from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 2nd. One research analyst has rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $27.97.

NASDAQ MYL opened at $18.78 on Monday. The company has a quick ratio of 0.84, a current ratio of 1.43 and a debt-to-equity ratio of 1.17. Mylan NV has a 52-week low of $16.63 and a 52-week high of $34.46. The business’s 50-day moving average price is $18.30 and its 200 day moving average price is $18.91. The firm has a market cap of $9.69 billion, a P/E ratio of 4.10, a P/E/G ratio of 1.01 and a beta of 1.75.

Mylan (NASDAQ:MYL) last announced its quarterly earnings data on Tuesday, November 5th. The company reported $1.17 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.14 by $0.03. Mylan had a return on equity of 18.80% and a net margin of 0.42%. The company had revenue of $2.96 billion for the quarter, compared to analyst estimates of $3.01 billion. During the same quarter in the previous year, the company earned $1.25 EPS. The firm’s revenue for the quarter was up 3.5% compared to the same quarter last year. As a group, analysts anticipate that Mylan NV will post 4.31 earnings per share for the current year.

About Mylan

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.

Recommended Story: The basics of gap trading strategies

Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan NV (NASDAQ:MYL).

Institutional Ownership by Quarter for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.